Gabriella Sozzi1, Mattia Boeri, Marta Rossi, Carla Verri, Paola Suatoni, Francesca Bravi, Luca Roz, Davide Conte, Michela Grassi, Nicola Sverzellati, Alfonso Marchiano, Eva Negri, Carlo La Vecchia, Ugo Pastorino. 1. Gabriella Sozzi, Mattia Boeri, Carla Verri, Paola Suatoni, Luca Roz, Davide Conte, Michela Grassi, Tumor Genomics Unit; Ugo Pastorino, Thoracic Surgery Unit; Alfonso Marchiano, Radiology Unit, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Nazionale dei Tumori; Marta Rossi, Francesca Bravi, Eva Negri, Carlo La Vecchia, IRCCS-Istituto di Ricerche Farmacologiche "Mario Negri"; Francesca Bravi and Carlo La Vecchia, University of Milan, Milan; and Nicola Sverzellati, University of Parma, Parma, Italy.
Abstract
PURPOSE: Recent screening trial results indicate that low-dose computed tomography (LDCT) reduces lung cancer mortality in high-risk patients. However, high false-positive rates, costs, and potential harms highlight the need for complementary biomarkers. The diagnostic performance of a noninvasive plasma microRNA signature classifier (MSC) was retrospectively evaluated in samples prospectively collected from smokers within the randomized Multicenter Italian Lung Detection (MILD) trial. PATIENTS AND METHODS: Plasma samples from 939 participants, including 69 patients with lung cancer and 870 disease-free individuals (n = 652, LDCT arm; n = 287, observation arm) were analyzed by using a quantitative reverse transcriptase polymerase chain reaction-based assay for MSC. Diagnostic performance of MSC was evaluated in a blinded validation study that used prespecified risk groups. RESULTS: The diagnostic performance of MSC for lung cancer detection was 87% for sensitivity and 81% for specificity across both arms, and 88% and 80%, respectively, in the LDCT arm. For all patients, MSC had a negative predictive value of 99% and 99.86% for detection and death as a result of disease, respectively. LDCT had sensitivity of 79% and specificity of 81% with a false-positive rate of 19.4%. Diagnostic performance of MSC was confirmed by time dependency analysis. Combination of both MSC and LDCT resulted in a five-fold reduction of LDCT false-positive rate to 3.7%. MSC risk groups were significantly associated with survival (χ1(2) = 49.53; P < .001). CONCLUSION: This large validation study indicates that MSC has predictive, diagnostic, and prognostic value and could reduce the false-positive rate of LDCT, thus improving the efficacy of lung cancer screening.
PURPOSE: Recent screening trial results indicate that low-dose computed tomography (LDCT) reduces lung cancer mortality in high-risk patients. However, high false-positive rates, costs, and potential harms highlight the need for complementary biomarkers. The diagnostic performance of a noninvasive plasma microRNA signature classifier (MSC) was retrospectively evaluated in samples prospectively collected from smokers within the randomized Multicenter Italian Lung Detection (MILD) trial. PATIENTS AND METHODS: Plasma samples from 939 participants, including 69 patients with lung cancer and 870 disease-free individuals (n = 652, LDCT arm; n = 287, observation arm) were analyzed by using a quantitative reverse transcriptase polymerase chain reaction-based assay for MSC. Diagnostic performance of MSC was evaluated in a blinded validation study that used prespecified risk groups. RESULTS: The diagnostic performance of MSC for lung cancer detection was 87% for sensitivity and 81% for specificity across both arms, and 88% and 80%, respectively, in the LDCT arm. For all patients, MSC had a negative predictive value of 99% and 99.86% for detection and death as a result of disease, respectively. LDCT had sensitivity of 79% and specificity of 81% with a false-positive rate of 19.4%. Diagnostic performance of MSC was confirmed by time dependency analysis. Combination of both MSC and LDCT resulted in a five-fold reduction of LDCT false-positive rate to 3.7%. MSC risk groups were significantly associated with survival (χ1(2) = 49.53; P < .001). CONCLUSION: This large validation study indicates that MSC has predictive, diagnostic, and prognostic value and could reduce the false-positive rate of LDCT, thus improving the efficacy of lung cancer screening.
Authors: Colin C Pritchard; Evan Kroh; Brent Wood; Jason D Arroyo; Katy J Dougherty; Melanie M Miyaji; Jonathan F Tait; Muneesh Tewari Journal: Cancer Prev Res (Phila) Date: 2011-12-12
Authors: Jason D Arroyo; John R Chevillet; Evan M Kroh; Ingrid K Ruf; Colin C Pritchard; Donald F Gibson; Patrick S Mitchell; Christopher F Bennett; Era L Pogosova-Agadjanyan; Derek L Stirewalt; Jonathan F Tait; Muneesh Tewari Journal: Proc Natl Acad Sci U S A Date: 2011-03-07 Impact factor: 11.205
Authors: Michaela B Kirschner; Steven C Kao; J James Edelman; Nicola J Armstrong; Michael P Vallely; Nico van Zandwijk; Glen Reid Journal: PLoS One Date: 2011-09-01 Impact factor: 3.240
Authors: Fabrizio Bianchi; Francesco Nicassio; Matteo Marzi; Elena Belloni; Valentina Dall'olio; Loris Bernard; Giuseppe Pelosi; Patrick Maisonneuve; Giulia Veronesi; Pier Paolo Di Fiore Journal: EMBO Mol Med Date: 2011-07-11 Impact factor: 12.137
Authors: A Cannistraci; G Federici; A Addario; A L Di Pace; L Grassi; G Muto; D Collura; M Signore; L De Salvo; S Sentinelli; G Simone; M Costantini; S Nanni; A Farsetti; V Coppola; R De Maria; D Bonci Journal: Oncogene Date: 2017-02-13 Impact factor: 9.867
Authors: Karen Chiam; Tingting Wang; David I Watson; George C Mayne; Tanya S Irvine; Tim Bright; Lorelle Smith; Imogen A White; Joanne M Bowen; Dorothy Keefe; Sarah K Thompson; Michael E Jones; Damian J Hussey Journal: J Gastrointest Surg Date: 2015-05-06 Impact factor: 3.452
Authors: Johannes F Fahrmann; Kyoungmi Kim; Brian C DeFelice; Sandra L Taylor; David R Gandara; Ken Y Yoneda; David T Cooke; Oliver Fiehn; Karen Kelly; Suzanne Miyamoto Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-08-17 Impact factor: 4.254